# Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

> **NCT06364072** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cessatech A/S** · enrollment: 155 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** CT001

## Key facts

- **NCT ID:** NCT06364072
- **Lead sponsor:** Cessatech A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-27
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364072, "Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06364072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*